	US 12,458,630 B2
	Combination therapy for cancer
Michael Karin, La Jolla, CA (US); and Hua Su, La Jolla, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Appl. No. 17/792,387
Filed by The Regents of the University of California, Oakland, CA (US)
PCT Filed Jan. 13, 2021, PCT No. PCT/US2021/013203 § 371(c)(1), (2) Date Jul. 12, 2022, PCT Pub. No. WO2021/146258, PCT Pub. Date Jul. 22, 2021.
Claims priority of provisional application 62/960,832, filed on Jan. 14, 2020.
Prior Publication US 2023/0068698 A1, Mar. 2, 2023
Int. Cl. A61K 31/427 (2006.01); A61K 31/137 (2006.01); A61K 31/366 (2006.01); A61P 35/00 (2006.01)

CPC A61K 31/427 (2013.01) [A61K 31/137 (2013.01); A61K 31/366 (2013.01); A61P 35/00 (2018.01)]

4 Claims

1. A method of inducing cell death of a cancer cell, the method comprising, contacting the cancer cell with:

(1) an inhibitor of macropinocytosis upregulation, wherein the inhibitor of macropinocytosis upregulation is an inhibitor of:

(a) NRF2 activity or expression selected from ML385 or Brusatol; or

(b) p62 activity or expression is selected from LP1-106 or XRK3F2;

and

(2) an autophagy inhibitor, wherein the autophagy inhibitor is selected from 3-Methyladenine (3-MA), LY294002, Bafilomycin A1 (Baf A1), Chloroquine (CQ), hydroxychloroquine (HCQ), ABT-737, an IKKα downregulator, obatoclax, Clarithromycin, Resveratrol, Quinacrine, 4-Acetylantroquinonol B, antroquinonol, Epigallocatechin gallate (EGCG), MRT68921 dihydrochloride, ULK1 inhibitors, MRT67307, SBI-0206965, ULK-100, ULK-101, DCC-3116, SAR405, Vps34-IN1 (PIK-III), SU1261, Vps34 inhibitors, or a combination thereof, thereby inducing cell death of the cancer cell.